Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIndependent Health Part D Prior Auth Policy Update…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentIndependent HealthPolicy N/A

    Prior authorization criteria for Medicare Part D formulary drugs

    Customize your policy alerts

    Sign up for all Independent Health policy alerts

    Know when Independent Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization requirements, clinical prerequisites, prescriber restrictions, and coverage durations for drugs on Independent Health's 2026 Medicare Advantage Part D formularies; applies to providers and pharmacies managing prescriptions for affected Medicare members.

    Policy Summary
    PayerIndependent Health
    PolicyPrior authorization criteria for Medicare Part D formulary drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before dispensing listed drugs to avoid non-coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026formulary year
    Medicare Advantage Part Dprogram governed
    1 yeartypical coverage duration
    Severalspecialty prescriber limits
    290document pages

    Coverage Criteria for Part D Drugs

    PAH (WHO Group 1) initial therapy

    Covered when ALL of the following are met:

    PAH initial authorization: Patient is ≥18 years; diagnosis confirmed by right heart catheterization with mean pulmonary arterial pressure >20 mm Hg and pulmonary arterial wedge pressure ≤15 mm Hg; for WHO Group 1 PAH pulmonary vascular resistance >2 Woods units; submit creatinine clearance (or data to calculate it) and pregnancy status; prescriber is cardiology or pulmonology; patient has tried and failed or is intolerant/contraindicated to both (1) sildenafil or tadalafil AND (2) ambrisentan or bosentan.see node text

    Coverage duration 1 year

    ARIKAYCE

    Covered when ALL of the following are met:

    ARIKAYCE initial authorization: Patient is ≥18 years; diagnosis of refractory Mycobacterium avium complex (MAC) lung disease; documentation patient tried a multi-drug regimen (e.g., ethambutol, a macrolide, and a rifamycin) for at least 6 months and failed; submit positive sputum culture obtained after treatment; prescriber is infectious diseases or pulmonology.
    Policy Summary
    PayerIndependent Health
    PolicyPrior authorization criteria for Medicare Part D formulary drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization before dispensing listed drugs to avoid non-coverage.
    SourceLink
    On This Page
    Coverage Criteria for Part D DrugsCodes, Strengths, and Key Numeric ThresholdsActions Required by Prescribers and PharmaciesInitial Therapy CriteriaReauthorization and Continuation RequirementsStep Therapy and Prior Trial RequirementsSite of Care and Medicare Part B vs Part D ConsiderationsDefinitions and Diagnostic ThresholdsPolicy Background
    6-month trial of regimen

    Coverage duration 1 year

    Immunomodulators/biologics initial therapy

    Covered when ALL of the following are met:

    Initial authorization for most biologics/targeted agents: Submit diagnosis and current/previous therapies; patient must have tried and failed or been intolerant to at least two preferred agents where possible (preferred list includes adalimumab biosimilar, Cosentyx, Enbrel, Rinvoq, Skyrizi, ustekinumab biosimilar, Xeljanz/XR); for all drugs except Otezla and Velsipity, negative baseline latent TB screen (PPD or IGRA) required prior to approval; prescriber restrictions apply by drug.failure to two preferred agents

    Annual reauthorization may require documentation of continued benefit; TB surveillance when exposure risk present.

    NEXLETOL / NEXLIZET

    Initial authorization requires ONE of the following options:

    NEXLETOL/NEXLIZET initial authorization options: Either (1) patient is currently using a statin (unless contraindicated) plus ezetimibe OR (2) patient has tried and failed or is intolerant to at least two statins OR one statin plus ezetimibe; at least one previously tried statin must be a hydrophilic statin.see node text

    Annual reauthorization requires continued use of prior lipid-lowering therapies unless contraindicated.

    BYLVAY

    Covered when ALL of the following are met:

    BYLVAY initial authorization: Diagnosis confirmed by molecular genetic testing; documentation of cholestasis by one of: total serum bile acid > age-adjusted ULN, increased conjugated bilirubin, GGT > age-adjusted ULN, fat-soluble vitamin deficiency, or intractable pruritus attributable to liver disease with drug-induced pruritus ruled out; attestation drug-induced pruritus ruled out; patient has tried and failed or is intolerant to at least two of: cholestyramine, naltrexone, rifampin, ursodiol.failure to ≥2 prior agents

    Initial coverage 6 months then 1 year; submit liver function testing at reauthorization.

    CABLIVI

    Covered when ALL of the following are met:

    CABLIVI authorization: Diagnosis of covered use (aTTP); confirm drug will be given with plasma exchange and immunosuppressive therapy; age ≥18 years; prescriber restricted to cardiology, hematology, or immunology; if not first use, submit prior aTTP recurrences while on caplacizumab.

    Coverage duration 3 months; reauthorization not authorized if >2 recurrences of aTTP while on therapy.

    Initial authorization requirements (cholestasis)

    Covered when ALL of the following are met:

    Cholestasis therapy initial criteria: Diagnosis confirmed by molecular genetic testing; documentation of cholestasis defined as (1) total serum bile acid > age-adjusted ULN OR (2) increased conjugated bilirubin OR (3) GGT > age-adjusted ULN OR (4) fat-soluble vitamin deficiency or intractable pruritus attributable to liver disease with drug-induced pruritus ruled out.see text

    Must also provide attestation drug-induced pruritus ruled out and submit current or previous therapies used to treat the condition.

    Step therapy (cholestasis)

    Prior therapy requirement for initial authorization:

    Prior therapies tried/failed: Patient must have tried and failed to have an adequate response to or had an intolerance to at least two of: cholestyramine, naltrexone, rifampin, ursodiol.>=2 agents

    Applies to initial authorization only.

    Caplacizumab

    Covered when ALL of the following are met:

    Caplacizumab criteria: Diagnosis of aTTP; confirmation drug will be given with plasma exchange and immunosuppressive therapy; age ≥18 years; prescriber restricted to cardiology, hematology, or immunology.

    Coverage duration 3 months; if not first use, coverage denied if >2 recurrences while on therapy.

    Camzyos (hypertrophic cardiomyopathy)

    Covered when ALL of the following are met:

    Camzyos criteria: Attestation patient has exertional symptoms consistent with NYHA class II or III, LV outflow tract gradient ≥50 mm Hg at rest/Valsalva/after exercise, LV wall thickness ≥15 mm (≥13 mm if familial), submission of current LVEF and pregnancy status; age ≥18; prescriber restricted to cardiology; patient has tried and failed or is intolerant/contraindicated to both a beta-blocker and a non-DHP calcium channel blocker.see text

    Exclude if LVEF <55% or on disallowed concomitant medications; coverage duration 1 year.

    Dupixent (by indication)

    Dupixent is covered by indication when ALL of the following are met:

    Dupixent for atopic dermatitis (AD): Diagnosis of AD with ≥10% body surface area involvement; submission of current and previous therapies used to treat the condition; patient tried and failed or is intolerant to at least a moderate strength topical corticosteroid for ≥4 weeks unless contraindicated.>=10% BSA

    Initial authorization 6 months then 1 year; reauthorization requires documentation of clinical benefit.

    Dupixent for asthma: Diagnosis of asthma with pre-bronchodilator FEV1 <80% predicted (<90% in children) AND either blood eosinophils ≥150 cells/mcL within 6 weeks of initiation OR documentation asthma requires daily oral corticosteroid for control; patient must be on GINA-recommended regimen (ICS+LABA+LAMA) prior to biologic and provider must attest therapy will continue.FEV1 and eos thresholds

    Initial authorization 6 months then 1 year; reauthorization requires continued triple therapy and clinical benefit.

    Dupixent for COPD: Post-bronchodilator FEV1/FVC <0.7 AND post-bronchodilator FEV1 30%–80% predicted AND blood eosinophils ≥300 cells/mcL within 6 weeks AND documentation patient is symptomatic (mMRC ≥2 or CAT ≥10); patient must be on stable ICS+LABA+LAMA for ≥90 days and attest therapy will continue.see text

    Reauthorization requires continued triple therapy and documented clinical benefit.

    Dupixent for CRSwNP: Documentation of nasal polyps and attestation patient has symptomatic nasal congestion; tried intranasal corticosteroid for ≥2 months unless contraindicated.

    Reauthorization: confirmation of intranasal corticosteroid use and clinical benefit.

    Dupixent for eosinophilic esophagitis (EoE): Upper endoscopy with biopsy showing ≥15 eos/HPF or 60 eos/mm2 AND compatible signs/symptoms (e.g., dysphagia, food impaction, reflux, chest/abdominal pain, nausea/vomiting); patient must have tried and failed an ≥8-week PPI course.>=15 eos/HPF

    Reauthorization requires documentation of clinical benefit (e.g., histologic remission).

    Dupixent for prurigo nodularis (PN): Documentation of pruritus lasting ≥6 weeks and presence of pruriginous firm, nodular lesions; submit therapies tried.>=6 weeks

    Reauthorization requires documentation of clinical benefit.

    Emgality (migraine)

    Covered when ALL of the following are met:

    Emgality acute migraine: For acute migraine treatment, patient must have tried and failed one triptan or have a contraindication to triptan use; age ≥18.

    Coverage duration 1 year.

    Emgality prevention: For episodic migraine prevention, documentation of fewer than 15 headache days per month; patient must have tried and failed Aimovig; initial authorization 3 months then 1 year; first reauthorization requires submission of on-treatment headache days demonstrating improvement from baseline.<15 headache days/month

    Doptelet (thrombocytopenia)

    Covered when ALL of the following are met:

    Doptelet for procedural thrombocytopenia: For thrombocytopenia in chronic liver disease scheduled for a procedure, submission of platelet count <50 x 10^9/L is required; coverage for procedure is 5 days.<50 x 10^9/L
    Doptelet for immune thrombocytopenia (ITP): Diagnosis of ITP with platelet count <30 x 10^9/L or <50 x 10^9/L with symptomatic bleeding; documentation patient has undergone splenectomy or tried and failed at least two ITP therapies from different classes (systemic corticosteroids, IVIG, danazol, fostamatinib, cytotoxics/immunosuppressants); initial ITP authorization initially 2 months then 1 year; first reauthorization requires platelet response ≥50 x 10^9/L after ≥4 weeks on maximum tolerated dose.see text

    Drugs requiring prior 5-HT3 antagonist failure for cancer-related nausea/vomiting

    Covered when ALL of the following are met:

    Chemotherapy-associated nausea/vomiting initial requirement: Diagnosis of nausea and vomiting associated with cancer therapy; patient is ≥18 years; patient tried and failed or was intolerant to at least one 5-HT3 receptor antagonist (e.g., granisetron, ondansetron); submit current/previous therapies used to treat the condition.

    If medication is full replacement for IV antiemetic within 48 hours of cancer treatment, may be Part B if prescriber indicates on prescription.

    Dupilumab (multiple indications)

    Covered when ALL of the following are met:

    Atopic dermatitis (Dupilumab) initial criteria: Documentation of ≥10% body surface area involvement; tried and failed a moderate strength topical corticosteroid for ≥4 weeks or contraindication documented; prescriber restrictions apply.

    Initial authorization 6 months then 1 year; reauthorization requires documentation of clinical benefit or maintenance.

    Asthma (biologic) initial criteria: Pre-bronchodilator FEV1 <80% predicted (<90% in children) AND either blood eosinophils ≥150 cells/mcL within 6 weeks or documentation patient requires daily oral corticosteroid; patient must be on GINA-recommended regimen (maximally tolerated ICS+LABA+LAMA) prior to biologic and provider must attest therapy will continue.

    Reauthorization requires continued background therapy and documented clinical benefit.

    COPD (biologic) initial criteria: Post-bronchodilator FEV1/FVC <0.7 and FEV1 30–80% predicted; blood eosinophils ≥300 cells/mcL within 6 weeks; symptomatic (mMRC ≥2 or CAT ≥10); must be on stable ICS+LABA+LAMA for ≥90 days and attest therapy will continue.

    Reauthorization requires continued triple therapy and clinical benefit.

    CRSwNP initial criteria: Evidence of nasal polyps and symptomatic nasal congestion; tried intranasal corticosteroid for ≥2 months or contraindication documented; attest intranasal corticosteroid will continue.

    Reauthorization: confirm intranasal steroid use and clinical benefit.

    Eosinophilic esophagitis initial criteria: Upper endoscopy with biopsy showing ≥15 eos/HPF or 60 eos/mm2; compatible signs/symptoms; tried and failed ≥8-week PPI course.

    Reauthorization requires documentation of clinical benefit (e.g., histologic remission).

    Eltrombopag and indications (ITP, thrombocytopenia with HCV, aplastic anemia)

    Covered when ALL of the following are met:

    Eltrombopag for ITP: Diagnosis of ITP with platelet count <30 x 10^9/L or <50 x 10^9/L with increased bleeding risk; submission of prior therapies tried and failed including splenectomy or two different ITP therapies (systemic corticosteroids, IVIG, danazol, fostamatinib, cytotoxics/immunosuppressants such as rituximab).

    First reauthorization requires updated platelet count showing improvement; subsequent reauth require maintenance of clinical benefit.

    Eltrombopag for thrombocytopenia with chronic HCV: Platelet count <75 x 10^9/L and attestation patient will receive interferon therapy for HCV.
    Eltrombopag for aplastic anemia: Platelet count <30 x 10^9/L and submission of immunosuppressive therapy plan or documentation of refractory disease and previous therapies tried and failed.

    Initial authorization 6 months for AA.

    FABHALTA and FILSPARI (IgAN, PNH, C3G) coverage

    Covered when ALL of the following are met:

    FABHALTA for PNH: Flow cytometry confirming PNH clones and objective signs attributable to PNH (e.g., Hb <10 g/dL, LDH >1.5x ULN, thrombosis); attestation no severe hepatic impairment; patient tried and failed or is intolerant to eculizumab or ravulizumab (hemoglobin <10 g/dL after 6 months on stable dose).

    Annual reauthorization requires symptomatic or clinical improvement or maintenance of prior benefit.

    FILSPARI for primary IgA nephropathy: Biopsy-confirmed primary IgA nephropathy with 24-hour urine protein ≥0.5 g/day or UPCR ≥0.8 g/g; patient must have tried and failed or be intolerant to maximally tolerated ACE inhibitor or ARB prior to initial authorization; prescriber restricted to immunology/nephrology.

    Reauthorization requires stabilization or improvement of UPCR or 24-hour urine protein from baseline.

    FABHALTA for C3G: Diagnosis confirmed by kidney biopsy and patient currently taking maximally tolerated ACE inhibitor or ARB plus systemic corticosteroid and/or mycophenolate; reauthorization requires documented clinically relevant response.

    GLP-1 receptor agonists and related products

    Covered when ALL of the following are met:

    GLP-1 receptor agonists (type 2 diabetes): Diagnosis of type 2 diabetes confirmed by medical record, ICD-10, or laboratory evidence (A1c ≥6.5% or glucose thresholds); attestation patient is not receiving another GLP-1 agonist; age consistent with prescribing information.A1c >= 6.5%

    Off-label use for weight management is excluded from coverage under Medicare Part D; coverage duration 1 year.

    General product-specific PA criteria

    Covered when ALL of the following are met (examples across multiple products):

    General oncology/ specialty agent requirements: Diagnosis of covered use; submission of required diagnostic testing (e.g., mutation testing), pregnancy status for females of childbearing potential; prescriber restricted to oncology where specified; age ≥18 unless otherwise noted.

    Coverage duration typically 1 year; see product-specific nodes for exact requirements.

    GLP-1 agonists (e.g., Mounjaro, Ozempic, Rybelsus)

    Covered when ALL of the following are met:

    GLP-1 agonists (product-specific): Diagnosis of type 2 diabetes per criteria (A1c ≥6.5% or equivalent lab evidence); attestation patient is not receiving another GLP-1 agonist; age consistent with product labeling.A1c >= 6.5%

    Off-label weight management excluded under Medicare Part D; coverage duration 1 year.

    Immune globulin products (e.g., GAMMAGARD, PRIVIGEN)

    Covered when ALL of the following are met:

    Immune globulin (IVIG/SCIG) criteria: Diagnosis of covered indication; for ITP submit platelet count; for CLL submit IgG <600 mg/dL and recent serious infection; for CIDP provide unequivocal diagnosis and documentation of failure/intolerance to systemic corticosteroids; submit required labs and documentation of benefit.

    Acute/new starts = 3 months; renewals = 1 year; IV home infusion for primary immune deficiency may be Part B; reauthorization requires documentation of clinical benefit.

    JUXTAPID criteria

    Covered when ALL of the following are met:

    JUXTAPID (lomitapide) initial authorization: Diagnosis consistent with FDA indication (e.g., homozygous familial hypercholesterolemia) with documented functional LDL receptor mutation or equivalent testing; submission of baseline hepatic labs (ALT, AST, alkaline phosphatase, total bilirubin) and baseline lipid panel (LDL-C, TC, apoB, non-HDL-C); patient must have tried and failed evolocumab.baseline labs as listed

    Initial duration 6 months then yearly; exclusions: heterozygous FH, pregnancy, active liver disease, moderate/severe hepatic impairment; prescriber restricted to cardiology/lipidology/endocrinology.

    KISQALI — Initial Authorization

    Covered when ALL of the following are met:

    KISQALI initial - diagnosis: Diagnosis of culture-proven systemic blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, or paracoccidioidomycosis.
    KISQALI initial - labs: Submission of baseline ALT, AST, total bilirubin, alkaline phosphatase, prothrombin time and INR.
    KISQALI initial - attestation: Prescriber attestation that potential benefits outweigh risks.

    Coverage duration = 6 months.

    KOMZIFTI — Authorization Criteria

    Covered when ALL of the following are met:

    KOMZIFTI authorization: Diagnosis of covered use with genetic tumor testing confirming HR-positive, HER2-negative; submission of QTcF interval and serum potassium and magnesium drawn within previous 6 months; age ≥18 and prescriber restricted to oncology.

    Coverage duration 1 year; exclude congenital long QT syndrome, QTcF ≥450 msec, uncorrected electrolyte abnormalities, and coadministration with strong CYP3A4 inducers or QT-prolonging drugs.

    l-glutamine for sickle cell disease — Initial Authorization

    Covered when ALL of the following are met:

    l-glutamine for sickle cell disease initial authorization: Diagnosis of sickle cell disease; patient must be using, have tried and failed, had inadequate response to, or had intolerance/contraindication to hydroxyurea prior to initial authorization; prescriber restricted to hematology.

    Coverage duration 1 year.

    LYNPARZA — Authorization Criteria (selected indications)

    Covered when ALL applicable indication-specific criteria are met:

    LYNPARZA - ovarian: For ovarian cancer: submission of BRCA/genomic instability testing and attestation patient is in complete or partial response to platinum-based chemotherapy.

    Coverage duration 1 year as applicable.

    LYNPARZA - breast: For breast cancer: submission of BRCA testing and attestation patient previously treated with chemotherapy; if HR-positive, endocrine therapy used or not possible.
    LYNPARZA - prostate: For castration-resistant prostate cancer: submission of homologous recombination repair gene mutation testing and attestation patient progressed after abiraterone or enzalutamide or will use olaparib with abiraterone and corticosteroid.

    Mepolizumab (and similar biologics) authorization

    Mepolizumab and similar biologics are covered when ALL of the following are met:

    Initial authorization for asthma: Patient is on GINA-recommended regimen (maximally-tolerated ICS+LABA+LAMA) prior to biologic therapy and provider attests regimen will continue after starting mepolizumab; submit baseline FEV1 and eosinophil counts as specified.FEV1 and eos thresholds as specified

    Reauthorization requires documentation of clinical improvement or maintenance of benefit.

    CRSwNP initial auth: Evidence of nasal polyps and attestation of symptomatic nasal congestion; trial of intranasal corticosteroid for ≥2 months unless contraindicated.

    Reauthorization requires documentation of benefit.

    EGPA/HES criteria: EGPA: eos% ≥10% or absolute eos ≥1000 cells/mm3 in prior 6 weeks AND disease ≥6 months relapsed/refractory to oral corticosteroids/immunosuppressives. HES: ≥2 flares requiring systemic therapy in past 12 months and eos ≥1000 cells/mcL with no identifiable non-hematologic secondary cause.

    Inbrija authorization

    Covered when ALL of the following are met:

    Inbrija initial authorization: Patient is ≥18 years; prescriber is neurology; patient experiencing 'off' episodes despite carbidopa/levodopa; patient has tried and failed or been intolerant to at least two different classes that reduce off episodes (COMT inhibitors, dopamine agonists, MAO-B inhibitors) unless contraindicated; not taking non-selective MAO inhibitors within 14 days; no asthma/COPD or other chronic underlying lung disease.

    Coverage duration 1 year; reauthorization requires confirmation of symptomatic improvement or maintenance.

    OFEV authorization

    Covered when ALL of the following are met:

    OFEV baseline and exclusions: Submission of liver function tests or Child-Pugh score and pregnancy status; HRCT scan within prior 12 months for chronic fibrosing ILD with progressive phenotype or systemic sclerosis-associated ILD.

    Exclusions: moderate or severe hepatic impairment (Child-Pugh B or C) and coadministration of dual P-gp/CYP3A4 inducer; reauthorization requires updated liver testing and confirmation of clinical benefit.

    Inbrija — Initial Therapy

    Covered when ALL of the following are met:

    Inbrija initial therapy: Patient ≥18 years; neurology prescriber; patient experiencing 'off' episodes despite carbidopa/levodopa; trial and failure or intolerance to medications from at least two classes that reduce off episodes (COMT inhibitors, dopamine agonists, MAO-B inhibitors) unless contraindicated; no non-selective MAOI within 14 days; no asthma/COPD/other chronic lung disease.

    Coverage duration 1 year.

    Lipid management — Initial Therapy (Repatha)

    Repatha is covered when ONE of the indication-specific sets is met:

    Repatha indications: For reduction of MACE or heterozygous familial hypercholesterolemia: patient tried and failed to achieve LDL <70 mg/dL despite ≥8 weeks high-intensity statin therapy, or experienced rhabdomyolysis on a statin, or had skeletal muscle intolerance to both atorvastatin and rosuvastatin resolved upon discontinuation. For homozygous familial hypercholesterolemia: similar LDL-related requirements or statin intolerance criteria apply.LDL <70 mg/dL after statin trial

    Age ≥10 for some indications; prescriber restrictions apply; coverage 1 year.

    Cushing's syndrome — Initial Therapy (Recorlev)

    Covered when ALL of the following are met:

    Recorlev initial authorization: Patient ≥18 years; prescriber is endocrinology; 24-hour UFC >1.5x ULN (~>50 micrograms or 145 nmol); pituitary surgery not an option or not curative; ECG including QTcF and liver function tests within 3 months; patient tried and failed at least one other therapy for Cushing's (e.g., mifepristone, pasireotide).UFC >1.5x ULN (~>50 micrograms)

    Coverage duration 1 year; reauthorization requires documentation of clinically relevant response (UFC reduction or maintenance).

    Product-specific initial authorization

    Covered when ALL of the following are met:

    Product-specific initial authorization: Diagnosis of covered use; product-specific diagnostic confirmation (e.g., F2/F3 fibrosis confirmation where applicable); patient is ≥18 years unless otherwise specified; prescriber within restricted specialty; other product-specific exclusions absent (e.g., moderate/severe hepatic impairment).

    Coverage duration typically 1 year; reauthorization requires documentation of clinical benefit as specified.

    Rivfloza (initial and reauthorization)

    Covered when ALL of the following are met:

    Rivfloza initial authorization: Diagnosis confirmed and AGXT mutation documented by enzyme analysis or genetic testing; 24-hour urinary oxalate (Uox) ≥0.7 mmol (normalized to BSA if <18 years); eGFR ≥30 mL/min/1.73 m2; no prior kidney or liver transplant; not used with lumasiran; prescriber nephrology/urology.Uox >= 0.7 mmol; eGFR >= 30

    Initial duration 6 months then 1 year for renewals; first reauthorization requires documentation of clinically relevant response (reduced Uox or plasma oxalate).

    Hepatitis C therapy

    Covered when ALL of the following are met:

    Sofosbuvir-velpatasvir initial authorization: Laboratory-confirmed HCV infection and genotype; attestation regarding ribavirin use for decompensated cirrhosis unless contraindicated; coverage duration 12 weeks.

    Transthyretin amyloid cardiomyopathy (Vyndamax/Vyndaqel)

    Covered when ALL of the following are met:

    ATTR-CM confirmation: Diagnosis of transthyretin amyloid cardiomyopathy confirmed by cardiac biopsy with amyloid deposits OR transthyretin precursor protein on immunohistochemistry OR technetium-99 SPECT/nuclear scintigraphy OR TTR genetic mutation plus cardiac involvement (ventricular wall thickening); documentation of heart failure with at least one prior hospitalization or clinical evidence requiring diuretic therapy; prescriber cardiology; age ≥18.

    Coverage duration 1 year; annual reauthorization requires confirmation of symptomatic or clinical improvement or maintenance.

    Psychiatric agent step therapy

    Covered when ALL of the following are met:

    Psychiatric agent step requirements: Diagnosis of covered use; prior trials and failures of specified alternatives required (e.g., aripiprazole and one other generic second-generation atypical antipsychotic for schizophrenia or acute bipolar I manic/mixed episodes); prescriber restricted to psychiatry.

    Coverage duration 1 year.

    Tafamidis / ATTR cardiomyopathy (example product entry)

    Covered when ALL of the following are met:

    Tafamidis (example) initial criteria: Diagnosis of transthyretin amyloid cardiomyopathy confirmed by biopsy, immunohistochemistry, technetium-99 SPECT, or TTR genetic mutation plus cardiac involvement; documentation of prior heart failure hospitalization or clinical evidence requiring diuretics; age ≥18; prescriber cardiology.

    Initial coverage 1 year; reauthorization requires documentation of symptomatic or clinical improvement or maintenance.

    Teriparatide / parathyroid hormone analogs

    Covered when ALL of the following are met:

    Teriparatide initial authorization: Diagnosis indicating high risk for fracture per defined criteria (history of hip/vertebral fracture or specified T-score/FRAX criteria); patient must have tried and failed or had intolerance/contraindication to at least one bisphosphonate (therapeutic failure defined as fracture or decrease in BMD while on bisphosphonate for ≥3 months); baseline serum calcium and BMD/fracture history submitted.

    Use >2 years generally not recommended; coverage typically 2 years unless continued high risk and reauthorization requirements met.

    VANRAFIA (primary IgA nephropathy)

    Covered when ALL of the following are met:

    VANRAFIA initial authorization: Primary IgA nephropathy confirmed by kidney biopsy; 24-hour urine protein ≥0.5 g/day or UPCR ≥0.8 g/g; patient is currently using or has contraindication/intolerance to a maximally-tolerated ACE inhibitor or ARB prior to initial authorization; prescriber restricted to nephrology/immunology.24-hour urine protein >=0.5 g/day or UPCR >=0.8 g/g

    Annual reauthorization requires documentation of clinically relevant response (stabilization or improvement of UPCR/24-hour urine protein).

    Tolvaptan (ADPKD vs hyponatremia formulations)

    Coverage varies by indication/formulation — covered when ALL applicable criteria are met:

    Tolvaptan for ADPKD (specific formulation): Diagnosis of rapidly progressing ADPKD defined by imaging (Mayo 1C–1E) or historical eGFR decline ≥3 mL/min/1.73 m2/year over 4 years or PROPKD score >6; prescriber restricted to nephrology; initial authorization 1 year.

    ADPKD formulation only; hyponatremia formulation not approved for ADPKD.

    Tolvaptan for hyponatremia (separate formulation): Clinically significant hyponatremia defined as serum sodium <125 mEq/L OR symptomatic <135 mEq/L resistant to fluid restriction; treatment limited to 30 days and must be initiated in setting where serum sodium can be closely monitored.serum sodium thresholds

    Coverage limited to 30 days initiation setting requirements apply.

    Verquvo (vericiguat) — HFrEF

    Covered when ALL of the following are met:

    Verquvo (vericiguat) initial criteria: Diagnosis of HFrEF with either hospitalization for heart failure within prior 6 months OR outpatient IV diuretic use within prior 3 months; left ventricular ejection fraction <45%; submission of current/previous heart failure therapies showing use of ACE inhibitor/ARB/sacubitril-valsartan, beta-blocker, and mineralocorticoid receptor antagonist each at maximally tolerated doses (or documentation why not); pregnancy status for females of childbearing potential; prescriber restricted to cardiology.LVEF <45%

    Coverage duration 1 year; exclude concurrent use of another sGC stimulator or PDE-5 inhibitor and pregnancy.

    VEOZAH (vasomotor symptoms)

    Covered when ALL of the following are met:

    VEOZAH initial authorization: Patient must have tried and failed or had intolerance to at least two prior systemic hormone therapies or FDA-approved/compendia-supported non-hormonal therapies from different medication classes (e.g., SSRI, SNRI, clonidine, gabapentin); submit eGFR and liver function testing prior to authorization.

    Exclusions include coadministration with CYP1A2 inhibitors, severe renal impairment/ESRD, known cirrhosis, or aminotransferase/total bilirubin ≥2x ULN; coverage duration 1 year; reauthorization requires documentation of symptomatic or clinical improvement.

    Initial Therapy - vasomotor symptoms product

    Covered when ALL of the following are met:

    Initial therapy - vasomotor symptoms product: Patient has tried and failed or had intolerance to at least two prior systemic hormone therapies or compendia-supported non-hormonal therapies from at least two different medication classes; submit diagnosis, eGFR, liver function testing, and prior/current therapies used to treat condition.

    Authorization 1 year; reauthorization requires confirmation of symptomatic improvement or maintenance; exclusions as noted for renal/hepatic disease and interacting drugs.

    Initial Therapy - VERQUVO

    Covered when ALL of the following are met:

    VERQUVO initial therapy: Documentation of HFrEF with either hospitalization for HFrEF within previous 6 months or outpatient IV diuretic use within previous 3 months, and LVEF <45%; patient's regimen must include ACE inhibitor/ARB/sacubitril-valsartan, a beta-blocker, and an MRA each at maximally tolerated doses or documentation why not; pregnancy status; prescriber restricted to cardiology.LVEF <45%

    Coverage duration 1 year; exclude pregnancy and concomitant use of another sGC stimulator or PDE-5 inhibitor.

    Initial Therapy - VIJOICE

    Covered when ALL of the following are met:

    VIJOICE initial therapy: Submission of test confirming presence of PIK3CA mutation; diagnostic imaging showing at least one target lesion with provider attestation patient has severe or life-threatening disease; exclusion for coadministration with strong CYP3A4 inducers.

    Initial authorization 6 months then 1 year; reauthorization requires objective documentation of benefit or maintenance.

    Initial and Reauthorization Therapy - WEGOVY

    Covered when ALL of the following are met (selected indications):

    WEGOVY for MACE indication: Documentation of established cardiovascular disease (prior MI, prior stroke, or symptomatic PAD defined by ABI <0.85 at rest, prior peripheral arterial revascularization, or amputation due to atherosclerotic disease), BMI ≥25 kg/m2, attestation patient is not using semaglutide for diabetes, and submission of cardiovascular risk factor medication regimen.BMI >=25 kg/m2

    Initial duration 32 weeks then 1 year for reauthorization; weight management indication excluded under Medicare Part D.

    WEGOVY for MASH indication: Confirmation of F2 or F3 fibrosis by biopsy or elastography and submission of liver function testing or Child-Pugh score; first reauthorization requires documentation of resolution or improvement/stabilization of fibrosis from baseline.F2 or F3 fibrosis

    Initial duration 32 weeks then 1 year.

    Indication-specific Criteria - XIFAXAN

    Covered when ALL applicable indication-specific criteria are met:

    XIFAXAN for HE: For hepatic encephalopathy (HE): diagnosis and prior trial/intolerance to lactulose required; coverage duration 1 year.
    XIFAXAN for IBS-D: For IBS-D: document number of prior 14-day courses of rifaximin in lifetime; must have tried and failed at least two specified medication classes; maximum of three 14-day courses per lifetime; coverage 14 days.max 3 lifetime courses
    XIFAXAN for SIBO: For SIBO: positive carbohydrate breath test required and prior failure/intolerance to at least two other antibiotics with evidence; maximum of two 14-day courses per 365 days; coverage 14 days.max 2 courses per 365 days

    XOSPATA

    Covered when documentation and restrictions below are satisfied:

    XOSPATA coverage: Diagnosis of covered use; confirmed FLT3 mutation; baseline serum potassium and magnesium levels; age ≥18; prescriber restricted to hematology/oncology; coverage duration 1 year; exclude uncorrected hypokalemia or hypomagnesemia and coadministration with dual strong CYP3A/P-gp inducers.

    All FDA-approved indications covered.

    XPOVIO

    Covered when documentation and prior therapy requirements are met:

    XPOVIO coverage: Diagnosis of covered use; pregnancy status for females of childbearing potential; age ≥18; prescriber restricted to hematology/oncology; coverage duration 1 year; for multiple myeloma in combination with bortezomib+dexamethasone documented failure of ≥1 prior therapy; for relapsed/refractory multiple myeloma documented failure of ≥4 prior systemic therapy lines including ≥2 proteasome inhibitors, ≥2 immunomodulatory agents, and an anti-CD38 monoclonal antibody.

    All FDA-approved indications covered.

    XURIDEN

    Covered when baseline labs and follow-up documentation provided:

    XURIDEN coverage: Diagnosis of covered use; submission of baseline CBC with neutrophil count and MCV and baseline urine orotic acid; coverage duration 1 year; annual reauthorization requires documentation of improvement or stabilization of urine orotic acid, neutrophil count, and MCV.

    All FDA-approved indications covered.

    ZEJULA

    Covered when testing and prior chemotherapy documentation are provided as applicable:

    ZEJULA coverage: Diagnosis of covered use; pregnancy status for females of childbearing potential; documentation of response to platinum-based chemotherapy as applicable; for germline BRCA-mutated recurrent epithelial ovarian/fallopian tube/primary peritoneal cancer submit test confirming deleterious BRCA mutation; prescriber restricted to oncology; coverage duration 1 year.

    All FDA-approved indications covered.

    ZILBRYSQ

    Covered when diagnostic confirmation, severity, vaccination, and prior therapy trials are documented:

    ZILBRYSQ initial coverage: Diagnosis confirmed by history of abnormal neuromuscular transmission tests or improvement with acetylcholinesterase inhibitors and positive AChR-Ab; MGFA class II–IV; baseline MG-ADL ≥6; attestation patient will not concurrently use rituximab or eculizumab; submission of current/previous therapies; attestation patient has received meningococcal vaccination (A, B, C, W, Y) and no unresolved N. meningitidis infection.

    Initial authorization requires trial and inadequate response to at least one drug in two of three classes (acetylcholinesterase inhibitors, corticosteroids, non-steroidal immunosuppressives); initial 6 months then 1 year; reauthorization requires documented improvement and maintenance plus vaccination status.

    ZORYVE

    Covered for plaque psoriasis when ALL of the following are met:

    ZORYVE coverage: Diagnosis of plaque psoriasis (atopic dermatitis excluded); submission of percent body surface area affected and current/previous therapies; age ≥6; prescriber dermatology (PA not required for dermatology prescribers); initial authorization requires failure/intolerance to at least one Class/Group 3 high-potency topical corticosteroid AND one other prescription topical agent for plaque psoriasis, or current use of systemic medication for plaque psoriasis.

    Coverage duration 1 year; reauthorization requires confirmation of symptomatic or clinical improvement or maintenance.

    ZURZUVAE

    Covered with postpartum timing and prescriber restrictions:

    ZURZUVAE coverage: Diagnosis of postpartum depression and attestation patient is within 12 months postpartum; age ≥18; prescriber restricted to gynecology, obstetrics, or psychiatry.

    Coverage duration 14 days; only one 14-day course allowed per plan year.

    ZYDELIG

    Covered when safety and prior therapy documentation are provided:

    ZYDELIG coverage: Diagnosis of covered use; attestation therapy will be coadministered with rituximab; documentation of at least one previous line of systemic therapy; pregnancy status for females of childbearing potential; age ≥18; prescriber restricted to hematology/oncology.

    Coverage duration 1 year; exclusions include history of toxic epidermal necrolysis, untreated active infection, or coadministration with strong CYP3A inducers.

    ZYKADIA

    Covered when ALK testing and safety checks are provided:

    ZYKADIA coverage: Diagnosis of ALK-positive tumor confirmed by testing; pregnancy status for females of childbearing potential; age ≥18; prescriber restricted to oncology.

    Coverage duration 1 year; exclusion for coadministration with strong CYP3A inducers.

    Coverage is denied when routine safety or clinical exclusions are met. Examples applicable across multiple products include: pregnancy; severe hepatic impairment (Child‑Pugh class C); severely reduced renal function (creatinine clearance < 15 mL/min or dialysis); and concurrent use of contraindicated agents such as nitrates or nitric oxide donors or phosphodiesterase inhibitors where noted. Prior authorization requests must include required baseline testing (e.g., creatinine clearance or data to calculate it) and pregnancy status for females of childbearing potential; failure to provide required information or presence of these exclusion conditions will result in non‑coverage per the product criteria.

    BENLYSTA (belimumab) is not eligible for coverage when the patient has severe active central nervous system lupus or is currently receiving other biologic therapies or intravenous cyclophosphamide. Initial authorization requires documentation the patient is using standard therapy (systemic corticosteroids, antimalarials, or immunosuppressants) and submission of an autoantibody‑positive test (ANA and/or anti‑dsDNA); absence of required documentation or presence of the noted exclusions precludes approval.

    Chenodal (chenodeoxycholic acid) will be excluded when standard hepatic or biliary contraindications are present, including pregnancy, known hepatocyte dysfunction, or bile duct abnormalities (for example, intrahepatic cholestasis, primary biliary cirrhosis, or sclerosing cholangitis). Requests are also excluded when imaging or surgical factors (e.g., radiopaque stones, nonvisualizing gallbladder after two dye doses, compelling need for gallbladder surgery) are documented. Safety beyond 24 months is not established and extended use will not be authorized.

    Camzyos (mavacamten) is excluded if the patient’s cardiac function does not meet safety thresholds — specifically if LVEF is less than 55%. Coadministration with disallowed interacting cardiac drugs (for example, combinations of non‑DHP calcium channel blockers plus beta‑blockers, disopyramide, ranolazine) or with specified strong CYP inhibitors/inducers also excludes use. Prior authorization requires documentation of LV outflow tract gradient, LV wall thickness, current LVEF and pregnancy status; presence of exclusionary findings prevents approval.

    GLP‑1 receptor agonists listed in this policy require coverage for labeled indications only. Off‑label uses are excluded; in particular, requests for GLP‑1 agonists for primary weight management (off‑label weight loss) are not approved under Medicare Part D. Prior authorization for GLP‑1s for diabetes requires documentation of type 2 diabetes per the criteria; absence of an indicated diagnosis or requests for weight‑loss use will be denied.

    Independent Health will not authorize GLP‑1 agonists when the sole or primary intent is weight management. Coverage is limited to FDA‑approved metabolic/diabetes indications and requires supporting documentation (e.g., A1c ≥ 6.5% or other laboratory/medical record evidence). Off‑label weight‑loss indications are explicitly excluded and treated as not covered.

    JUXTAPID (lomitapide) is excluded for patients with heterozygous familial hypercholesterolemia, for pregnant patients, and for those with moderate or severe hepatic impairment (Child‑Pugh B or C) or active liver disease. Coadministration with moderate or strong CYP3A4 inhibitors is also an exclusion. Baseline hepatic testing and lipid panel are required for any request; presence of the exclusion criteria will result in denial.

    For hereditary angioedema (HAE) products, requests for routine prophylactic therapy are excluded where the policy specifies attacks only or limits prophylaxis; approval requires documentation that prophylaxis is medically necessary per the product‑specific criteria (disease activity, attack frequency, and burden). Additionally, select antifungal and hepatic‑risk products required baseline liver testing and exclude patients with acute or chronic liver disease; such hepatic exclusions must be met before authorization will be considered.

    Codes, Strengths, and Key Numeric Thresholds

    Drug strengths noted in product listmixed
    50-75 & 150 MG, 50-25-37.5 & 75 MGDosage strengths listed for Trikafta oral therapy pack
    Biologic product strengthsmixed
    140 MG/ML, 70 MG/MLAimovig autoinjector strengths
    Covered NDC/product formulationsNDC | mixedCovered
    N/ADrug product list including MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY formulations
    Covered products (examples)mixedCovered
    CORLANOR ORAL SOLUTIONProduct listed
    diclofenac sodium external gel 3 %Product listed
    ivabradine hcl oral tablet 5 mg, 7.5 mgProduct listed
    PCSK9 productsmixedCovered
    REPATHAProduct listed
    REPATHA PUSHTRONEX SYSTEMProduct listed
    REPATHA SURECLICKProduct listed
    Products referenced in this excerptmixed
    No codes listed
    Products listed (drug names only)mixed
    No codes listed
    Products with therapy pack listingsmixed
    XPOVIO (multiple pack/dose listings)XPOVIO oral tablet therapy packs: multiple dosing schedules listed (10 mg, 40 mg, 50 mg, 60 mg, 80 mg variants).
    Indexed therapy packsmixed
    VALTOCOVALTOCO nasal liquid therapy pack listings referenced
    inv-101: Mean pulmonary arterial pressure
    Mean pulmonary arterial pressure (mPAP)> 20 mm Hg
    Age restriction≥ 18 years
    Required diagnostic testRight heart catheterization confirming mPAP
    inv-102: Pulmonary arterial wedge pressure
    Pulmonary arterial wedge pressure (PAWP)≤ 15 mm Hg
    ContextMeasured at right heart catheterization for PAH workup
    Documentation requiredSubmit PAWP with right heart catheterization results
    inv-103: Pulmonary vascular resistance for PAH (WHO Group 1)
    Pulmonary vascular resistance (PVR) — WHO Group 1 PAH> 2 Woods units
    Measurement contextReported on right heart catheterization for PAH diagnosis
    DocumentationSubmit PVR when requesting PAH therapy authorization
    inv-104: Pulmonary vascular resistance for CTEPH (WHO Group 4)
    Pulmonary vascular resistance (PVR) — CTEPH (WHO Group 4)> 3 Woods units
    Supporting imagingEvidence of chronic pulmonary embolism on CT or V/Q scan required
    Operability attestationAttestation patient has inoperable disease or persistent/recurrent disease
    inv-105: Platelet count threshold for AYVAKIT in mastocytosis
    AYVAKIT mastocytosis platelet thresholdPlatelet count < 50 x 10^9/L is an exclusion
    Required labSubmit platelet count for advanced or indolent systemic mastocytosis
    Age restriction18 years or older
    inv-106: LV outflow tract obstruction gradient
    LV outflow tract obstruction gradient>= 50 mm Hg (rest, Valsalva, or after exercise)
    Associated requirementAttestation of exertional symptoms consistent with NYHA II–III
    Prescriber restrictionRestricted to cardiology
    inv-107: Left ventricular wall thickness
    Left ventricular wall thickness>= 15 mm (>=13 mm if familial)
    DocumentationSubmit measurement and current LVEF with authorization request
    Age restriction18 years or older
    inv-108: Asthma blood eosinophil
    Asthma blood eosinophil threshold>= 150 cells/mcL (within 6 weeks of initiation)
    Alternate timeframe>= 300 cells/mcL within 12 months of initiation (where specified)
    Required testingSubmit blood eosinophil count with initial authorization for asthma biologics
    inv-109: COPD blood eosinophil
    COPD blood eosinophil threshold>= 300 cells/mcL (within 6 weeks of therapy initiation)
    Spirometry requirementPost-bronchodilator FEV1/FVC <0.7 and FEV1 30–80% predicted
    Clinical requirementDocumentation patient is symptomatic (mMRC ≥2 or CAT ≥10)
    inv-110: Platelet count for procedure in chronic liver disease
    Platelet count for procedure in chronic liver disease< 50 x 10^9/L
    Use caseThreshold applies when scheduling a procedure in chronic liver disease patients
    Submit labsSubmit current platelet count with authorization request
    inv-111: Platelet count for ITP
    ITP platelet thresholds< 30 x 10^9/L OR < 50 x 10^9/L with symptomatic bleeding
    Initial authorization requirementDocument prior therapies tried and failed (e.g., corticosteroids, IVIG, splenectomy) for ITP
    Reauthorization metricFirst reauthorization requires platelet response ≥50 x 10^9/L after ≥4 weeks on max tolerated dose
    inv-112: Laboratory thresholds (examples consolidated)
    Consolidated laboratory thresholds (examples)Asthma eos ≥150 cells/mcL; COPD eos ≥300 cells/mcL; ITP platelet <30 x10^9/L (or <50 with bleeding); UPCR ≥1.5 g/g or 24-h protein thresholds per nephrology agents
    PurposeThese examples represent commonly applied objective lab cutoffs for initial authorization
    DocumentationSubmit the specific laboratory result that matches the drug-specific requirement
    inv-113: QTcF interval
    QTcF interval (general exclusion threshold)>= 450 msec (exclusion for certain agents at initiation)
    Drug-specific thresholdsSome agents use higher cutoffs (e.g., >=480 msec for select drugs) — confirm per product criteria
    Required testSubmit ECG including QTcF with authorization where specified
    inv-114: eGFR exclusion threshold
    eGFR exclusion threshold (examples)eGFR < 30 mL/min/1.73 m2 excludes some therapies; specific entries cite <25 mL/min/1.73 m2 as exclusion for certain agents
    Rivfloza specificRivfloza requires eGFR >= 30 mL/min/1.73 m2 for initiation
    DocumentationSubmit eGFR or creatinine clearance with authorization request

    Actions Required by Prescribers and Pharmacies

    Prior Authorization

    Obtain prior authorization before dispensing

    Prior authorization is required for drugs listed with 'PA' on the Medicare Advantage Part D formularies; approval must be obtained from the plan before dispensing to avoid non-coverage.

    Prior Authorization

    Age‑based PA applies to select analgesic combos (65+)

    PA applies to certain analgesic combination products only for patients aged 65 years and older; these PA requirements do not apply to patients 64 years or younger.

    Prior Authorization

    Document failure/intolerance to ≥2 listed therapies before initial approval

    For initial authorization of cholestasis-targeted therapy (e.g., BYLVAY), the patient must have tried and failed or been intolerant to at least two of cholestyramine, naltrexone, rifampin, or ursodiol; initial coverage is for 6 months with reauthorization then 1 year.

    Prior Authorization

    Authorize caplacizumab only with plasma exchange + immunosuppression; age ≥18; 3‑month limit

    Caplacizumab (CABLIVI) requires the requester confirm the drug will be administered with plasma exchange and immunosuppressive therapy, patient age ≥18, and coverage is limited to 3 months; if not first use, prior aTTP recurrences while on caplacizumab must be submitted and >2 recurrences will preclude reauthorization.

    Prior Authorization

    Dupixent: 6‑month initial approval, specialty prescriber, and required testing

    Dupixent initial authorization is for 6 months (then 1 year on renewal); prescriber specialty is restricted by indication; submit condition‑specific objective data (e.g., ≥10% BSA for AD, pre‑bronchodilator FEV1 and blood eosinophils for asthma) and documentation of current/prior therapies.

    Prior Authorization

    Supply prior‑therapy trial/failure documentation with PA requests

    Many products require prior authorization and documented evidence that specified prior therapies were tried and failed (or were contraindicated/intolerant) before approval; submit documentation of those prior therapies with the request.

    Prior Authorization

    Most PAs grant 1‑year coverage unless noted otherwise

    Prior authorization is required for listed products generally; coverage duration is typically 1 year unless a product‑specific exception is noted.

    Prior Authorization

    IVIG: acute starts 3 months; renewals 1 year; home IVIG may be Part B

    For immune globulin (IVIG/SCIG) products: initial/acute starts are authorized for 3 months and renewals for 1 year; IV formulations administered in the home for primary immune deficiency may be covered under Medicare Part B — submit indication‑specific documentation.

    Prior Authorization

    KISQALI PA: baseline LFTs + culture‑proven diagnosis; 6‑month duration

    KISQALI for systemic fungal indications requires prior authorization with submission of baseline liver tests and documented culture‑proven diagnosis (blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, or paracoccidioidomycosis); coverage duration 6 months.

    Prior Authorization

    KOMZIFTI PA: genetic testing, ECG/electrolytes, age ≥18, oncology prescriber

    KOMZIFTI prior authorization requires tumor genetic testing confirming HR‑positive, HER2‑negative disease, submission of QTcF and serum potassium/magnesium within the prior 6 months, patient age ≥18, and oncology prescriber; coverage duration 1 year.

    Prior Authorization

    LYNPARZA PA: BRCA/HHRR testing and indication‑specific attestation

    LYNPARZA prior authorization requires submission of relevant genetic testing (BRCA or homologous recombination repair genes) and indication‑specific attestations (e.g., response to platinum‑based chemotherapy for ovarian cancer); coverage duration 1 year.

    Documentation Required

    Include diagnosis, prescriber specialty, age, and pregnancy status with PA

    Prior authorization requests must include required diagnostic documentation, prescriber specialty when restricted, applicable age limits, and pregnancy status where requested (examples shown across products).

    Prior Authorization

    Inbrija PA: neurology prescriber, age ≥18, trial of ≥2 medication classes required

    Inbrija requires prior authorization: prescriber restricted to neurology, patient age ≥18, 1‑year coverage; initial approval requires trials/failures or intolerance to at least two classes that reduce 'off' episodes (COMT inhibitors, dopamine agonists, MAO‑B inhibitors) unless contraindicated.

    Prior Authorization

    Pemazyre PA: FGFR testing, prior systemic therapy, oncology prescriber, age ≥18

    Pemazyre prior authorization requires documentation of FGFR1/FGFR2 genetic testing, prior systemic treatment for the indication, oncology prescriber, patient age ≥18, and excludes coadministration with moderate/strong CYP3A4 inducers; coverage 1 year.

    Prior Authorization

    PA requests must include diagnostic tests, prescriber specialty, age; typical 1‑year duration

    Prior authorization generally requires submission of specified diagnostic tests, prescriber specialty, age confirmation, and supports coverage for about 1 year for most agents (product exceptions noted).

    Prior Authorization

    Rivfloza: initial 6 months then 1‑year renewals; submit AGXT and Uox/eGFR

    Rivfloza initial authorization is for 6 months and reauthorization for 1 year thereafter; submit required genetic/biochemical confirmation (AGXT mutation and 24‑hour urinary oxalate) and baseline eGFR per product criteria.

    Prior Authorization

    PA typically authorizes 1‑year coverage

    Prior authorization is required for many listed products; coverage duration is commonly 1 year unless the product specifies otherwise.

    Prior Authorization

    PA required for VERQUVO and related products; 1‑year coverage

    VERQUVO and related products require prior authorization; coverage is generally 1 year and prescriber specialty may be restricted; some related products list prerequisite therapy requirements.

    Prior Authorization

    Verquvo PA: cardiology prescriber, LVEF <45% and recent HF event required

    Verquvo prior authorization requires adult HFrEF documentation (LVEF <45%, recent HF hospitalization or outpatient IV diuretic), pregnancy status, prescriber restricted to cardiology, and coverage duration 1 year.

    Prior Authorization

    XOSPATA PA: FLT3 testing, baseline electrolytes, hematology/oncology prescriber, age ≥18

    XOSPATA prior authorization requires documentation of FLT3 mutation, baseline potassium and magnesium, prescriber restricted to hematology/oncology, patient age ≥18, and coverage duration 1 year; uncorrected electrolyte abnormalities or coadministration with dual strong CYP3A/P‑gp inducers are exclusions.

    Prior Authorization

    XPOVIO PA: age ≥18, oncology prescriber, prior therapy failures documented

    XPOVIO prior authorization requires age ≥18, hematology/oncology prescriber, coverage 1 year, documentation of prior therapy failures for certain indications (e.g., multiple myeloma relapsed/refractory criteria).

    Documentation Required

    XURIDEN PA: baseline CBC, MCV, urine orotic acid; annual lab documentation for reauth

    XURIDEN prior authorization requires submission of baseline CBC with neutrophil count and MCV and baseline urine orotic acid; annual reauthorization requires documentation of improvement or stabilization of these labs.

    Prior Authorization

    ZEJULA PA: oncology prescriber, platinum response and BRCA testing as applicable

    ZEJULA prior authorization requires age ≥18, oncology prescriber restriction, coverage 1 year, documentation of response to platinum‑based chemotherapy, and BRCA testing where applicable.

    Prior Authorization

    ZILBRYSQ PA: neurology prescriber; initial 6 months then 1 year; step/rehab requirements

    ZILBRYSQ prior authorization is restricted to neurology; initial approval is 6 months then 1 year for renewals; initial trial/failure requirements across medication classes must be met and reauthorization requires documented symptomatic improvement and vaccination status.

    Prior Authorization

    ZORYVE PA: plaque psoriasis only, age ≥6, prior topical/systemic therapy required

    ZORYVE prior authorization is required for plaque psoriasis (atopic dermatitis excluded); age ≥6, PA not required if requested by dermatology prescribers, coverage 1 year; initial approval requires prior failure/intolerance to a high‑potency topical corticosteroid plus another topical agent or current systemic therapy.

    Prior Authorization

    ZURZUVAE PA: postpartum attestation, specialty prescriber, one 14‑day course

    ZURZUVAE prior authorization requires prescriber restricted to gynecology/obstetrics/psychiatry, attestation patient is within 12 months postpartum, coverage limited to a single 14‑day course per plan year.

    Prior Authorization

    ZYDELIG PA: oncology prescriber, coadministration with rituximab, prior therapy documented

    ZYDELIG prior authorization requires age ≥18, hematology/oncology prescriber, attestation therapy will be coadministered with rituximab, documentation of at least one prior systemic therapy, pregnancy status for females of childbearing potential, and coverage duration 1 year.

    Prior Authorization

    ZYKADIA PA: ALK testing, oncology prescriber, age ≥18

    ZYKADIA prior authorization requires submission of test confirming ALK‑positive tumor, pregnancy status for females of childbearing potential, prescriber restricted to oncology, patient age ≥18, and coverage 1 year.

    Step Therapy

    Biologic step: fail ≥2 preferred agents and complete TB screening when required

    For many biologic agents (except Otezla and Velsipity), initial authorization requires failure or intolerance to at least two preferred agents where available; TB screening (PPD or IGRA) is required before initiation when applicable.

    Step Therapy

    NEXLETOL/NEXLIZET: statin ± ezetimibe trial or documented statin failures

    NEXLETOL/NEXLIZET initial authorization requires either current statin use (unless contraindicated) plus ezetimibe, or prior failure/intolerance to at least two statins or one statin plus ezetimibe; at least one previously tried statin must be a hydrophilic statin.

    Step Therapy

    Emgality prevention: fail Aimovig and document baseline headache days

    Emgality for migraine prevention requires documented failure or intolerance to Aimovig before initial approval; prevention criteria include documentation of <15 headache days/month and reauthorization requires on‑treatment headache days showing improvement.

    Step Therapy

    Camzyos: trial of beta‑blocker and non‑DHP CCB required

    Camzyos initial authorization requires trial and inadequate response or intolerance to both a beta‑blocker and a non‑DHP calcium channel blocker prior to approval.

    Step Therapy

    Document trials and failures of specified alternatives before approval

    Many specialty products (e.g., dupilumab, FABHALTA/FILSPARI) require documented failure of specified first‑line or alternative therapies prior to approval; provide records showing prior therapies tried and reasons for failure or intolerance.

    Step Therapy

    Oncology PAs: document required prior therapy trials/failures

    Selected oncology agents require documentation of prior lines or specific prior therapies (e.g., ROS1 agents require prior crizotinib or entrectinib failure; others require endocrine or chemotherapy trials) before authorization.

    Step Therapy

    l‑glutamine requires prior hydroxyurea trial/failure

    For l‑glutamine in sickle cell disease, initial authorization requires prior use, failure, intolerance, or inadequate response to hydroxyurea.

    Step Therapy

    LYBALVI: prior trials of generic olanzapine + another SGA required

    LYBALVI initial authorization requires failure or intolerance to generic olanzapine (with documentation of benefit but unacceptable weight gain) and one other specified generic second‑generation antipsychotic before approval.

    Step Therapy

    Mepolizumab (asthma): confirm maximal ICS+LABA+LAMA trial before biologic

    For mepolizumab and similar biologics in asthma, initial authorization requires the patient be on a GINA‑recommended maximal ICS+LABA+LAMA regimen prior to biologic initiation; reauthorization requires confirmation the inhaler regimen continues.

    Step Therapy

    Inbrija step: trial of ≥2 different classes required before approval

    Inbrija initial authorization requires documented trials/failures or intolerance to at least two different classes (COMT inhibitors, dopamine agonists, MAO‑B inhibitors) unless contraindicated.

    Step Therapy

    Inbrija: provide documentation of prior class trials/failures

    Inbrija step therapy requires prior failures of two classes that reduce off episodes (COMT inhibitors, dopamine agonists, MAO‑B inhibitors) unless contraindicated; include documentation of those trials with the PA request.

    Step Therapy

    Psychiatric/neurologic agents: document required prior trials/failures

    Prior trials and failures of specified alternatives are required for certain psychiatric and neurologic agents (e.g., aripiprazole plus another SGA for antipsychotics) and must be documented in the PA request.

    Step Therapy

    Teriparatide requires prior bisphosphonate trial/failure

    Parathyroid hormone analogs (e.g., teriparatide) require prior trial and failure or intolerance to at least one bisphosphonate for initial authorization; therapeutic failure is defined by fracture or decreased BMD while on bisphosphonate for ≥3 months.

    Step Therapy

    VEOZAH: fail ≥2 systemic/non‑hormonal therapies from different classes

    VEOZAH initial authorization requires failure/intolerance to at least two prior systemic hormone or non‑hormonal therapies from different classes for vasomotor symptoms; submit eGFR and liver function testing as requested.

    Documentation Required

    Tumor genetic testing and prior endocrine therapy required (e.g., TRUQAP)

    For select targeted therapies (e.g., TRUQAP/alpelisib), tumor genetic testing confirming the target mutation and progression on at least one endocrine‑based regimen (and use with fulvestrant where specified) must be submitted with the PA.

    Documentation Required

    Provide complete prior‑therapy histories when required

    Many products (including Verquvo and others) require documentation of prior trials or failures of specified therapies; include exact prior therapy names, dates, and reasons for discontinuation in the PA submission.

    Step Therapy

    ZILBRYSQ step: fail agents in 2 of 3 drug classes before approval

    For ZILBRYSQ initial authorization, document failure or inadequate response to at least one drug in two of three classes (acetylcholinesterase inhibitors, corticosteroids, non‑steroidal immunosuppressives) before approval.

    Step Therapy

    ZORYVE: prior topical corticosteroid + another topical agent required

    For ZORYVE initial authorization for plaque psoriasis, document prior failure/intolerance to at least one high‑potency topical corticosteroid and one other prescription topical agent (or current systemic therapy) before approval.

    Step Therapy

    XPOVIO: document prior therapy failures per indication (MM criteria)

    For XPOVIO in multiple myeloma combinations, document failure of at least one prior therapy; for relapsed/refractory myeloma provide documentation of failure of ≥4 prior systemic therapy lines including required classes.

    Documentation Required

    XURIDEN: baseline CBC/urine orotic acid and annual lab evidence for reauth

    For XURIDEN PA, submit baseline CBC with neutrophil count and MCV and baseline urine orotic acid; annual reauthorization must document improvement or stabilization of those labs.

    Documentation Required

    ZEJULA: document platinum response and BRCA testing as applicable

    ZEJULA PA requires documentation of response to platinum‑based chemotherapy and, for germline BRCA‑mutated disease, submission of test confirming a deleterious BRCA mutation.

    Documentation Required

    BYLVAY/cholestasis: submit molecular testing + objective cholestasis lab

    For cholestasis‑targeted therapies (e.g., BYLVAY) include molecular genetic testing confirming diagnosis and one objective cholestasis marker (age‑adjusted elevated total serum bile acids, increased conjugated bilirubin, GGT > ULN, fat‑soluble vitamin deficiency, or intractable pruritus with drug‑induced causes ruled out).

    Documentation Required

    PAH PA: submit right heart cath, hemodynamics, CrCl, pregnancy status

    Diagnosis documentation for PAH drugs must include right heart catheterization results, WHO Group classification, mean pulmonary arterial pressure >20 mm Hg, pulmonary arterial wedge pressure ≤15 mm Hg, PVR >2 Woods units (for WHO Group 1), creatinine clearance (or data to calculate it), and pregnancy status; prescriber restricted to cardiology or pulmonology.

    Documentation Required

    AYVAKIT: PDGFRA exon 18 (GIST) or platelet count (mastocytosis) required

    AYVAKIT PA requests for GIST must include test confirming PDGFRA exon 18 mutation; for systemic mastocytosis include platelet count; submit pregnancy status for females of childbearing potential.

    Documentation Required

    Submit Dupixent clinical measures (BSA, FEV1, eosinophils) with PA

    For Dupixent, submit diagnosis, current/previous therapies, and indication‑specific objective data (e.g., ≥10% BSA for AD; pre‑bronchodilator FEV1 and blood eosinophils or OCS dependence for asthma) as part of the PA request.

    Documentation Required

    Include objective disease‑specific documentation with PA

    Always include objective disease‑specific documentation requested per product (e.g., biopsies for eosinophilic esophagitis, platelet counts for ITP, genetic/molecular testing for targeted oncology agents) when submitting a PA.

    Documentation Required

    Provide EGFR mutation testing and pregnancy status when required

    Where requested, submit EGFR tumor testing (exon 19 deletions or exon 21 L858R) and pregnancy status for females of childbearing potential for relevant EGFR‑targeted agents.

    Documentation Required

    Submit LFTs/Child‑Pugh score for hepatically metabolized agents

    Provide baseline liver function tests or Child‑Pugh score when requested for hepatically metabolized agents or agents with hepatic safety considerations.

    Documentation Required

    JUXTAPID: submit baseline LFTs and lipid/genetic documentation

    For JUXTAPID, submit baseline hepatic labs (ALT, AST, alkaline phosphatase, total bilirubin) and lipid panel (LDL‑C, TC, apoB, non‑HDL‑C) and documentation of genetic or functional LDL receptor abnormality as specified.

    Documentation Required

    KISQALI: baseline LFTs, PT/INR and culture‑proven fungal infection required

    For antifungal KISQALI use, submit baseline liver tests (ALT, AST, total bilirubin, alkaline phosphatase), PT/INR, and documentation of a culture‑proven systemic fungal infection.

    Documentation Required

    KOMZIFTI: genetic tumor testing + QTcF and electrolytes required

    KOMZIFTI authorization requires submission of genetic tumor testing confirming HR+/HER2‑ disease and recent QTcF and electrolyte measurements (serum potassium and magnesium) plus pregnancy status for females of childbearing potential.

    Documentation Required

    LYNPARZA: genetic testing and prior therapy documentation required

    For LYNPARZA and similar agents, submit diagnostic genetic testing (BRCA or homologous recombination repair genes) and documentation of prior therapies as applicable for the indication.

    Documentation Required

    Attest surgery non‑option and provide disease‑specific attestations where required

    Include diagnosis of covered use and attest when surgery is not an option or not curative where indicated (e.g., selected endocrine or metabolic indications) and document diabetes or glucose intolerance when requested.

    Documentation Required

    Submit enzyme‑replacement exclusion rationale and CrCl when requested

    Provide enzyme‑replacement exclusion documentation and creatinine clearance (or data to calculate it) when requested for applicable products.

    Initial Therapy Criteria

    Reauthorization and Continuation Requirements

    Step Therapy and Prior Trial Requirements

    RequirementDetails
    Required prior use of preferred comparators
    For initial authorization of most immunomodulatory/biologic agents (exceptions: Otezla and Velsipity), patient must have tried and failed or been intolerant to at least two preferred agents (examples: adalimumab biosimilar, Cosentyx, Enbrel, Rinvoq, Skyrizi, ustekinumab biosimilar, Xeljanz/XR); baseline TB screening (PPD or IGRA) required prior to initiation where applicable.
    RequirementDetails
    Prior statin therapy or statin + ezetimibe required
    Initial authorization for NEXLETOL/NEXLIZET requires either (1) current statin use (unless contraindicated) plus ezetimibe, OR (2) prior trial and failure or intolerance to at least two statins OR one statin plus ezetimibe; at least one previously tried statin must be a hydrophilic statin. Annual reauthorization requires continued use of prior lipid-lowering therapies unless contraindicated.
    RequirementDetails
    Emgality reauthorization documentation
    For migraine prevention with Emgality, initial authorization for prevention requires failure or intolerance to Aimovig and documentation of fewer than 15 headache days per month; the first reauthorization requires submission of on-treatment headache days per month demonstrating improvement from baseline; maintenance reauthorizations require documented maintenance of clinical benefit.
    RequirementDetails
    Symptomatic improvement confirmation at reauthorization
    For products requiring reauthorization (example: Camzyos), each annual reauthorization must include confirmation of symptomatic or clinical improvement (or maintenance of a previously achieved improvement); documentation of the clinical benefit is required.
    RequirementDetails
    Documentation of prior therapies tried and failed required
    Initial authorization requests must submit current and prior therapies used to treat the condition; for many agents patients must have tried and failed or been intolerant to specified first-line or alternative therapies (examples: topical corticosteroids for AD, ACE inhibitor/ARB for IgAN, eculizumab/ravulizumab for PNH).
    RequirementDetails
    Step therapy example
    Some oncology-targeted agents require documented prior failure of specific therapies (example: ROS1-targeted agents require prior trial and failure or intolerance to crizotinib or entrectinib), which must be submitted with the authorization request.
    RequirementDetails
    Step therapy example
    Certain non-oncology agents require prior trials of indicated alternatives before initiation (example: some cardiometabolic agents require prior therapy such as Farxiga or Jardiance prior to approval where specified). Authorization requires documentation of those prior trials and outcomes.
    RequirementDetails
    Prior trial and failure or intolerance required
    Examples: for l‑glutamine in sickle cell disease, patient must be using, have tried and failed, had inadequate response to, or been intolerant/contraindicated to hydroxyurea prior to initial authorization; for LYBALVI initial authorization requires failure or intolerance to both generic olanzapine (with documentation of benefit but unacceptable weight gain) and one other generic second‑generation antipsychotic.
    RequirementDetails
    Step therapy required
    For biologic asthma therapies (example: mepolizumab), initial authorization requires failure or inadequate response to maximal inhaler therapy per GINA (ICS+LABA+LAMA) prior to biologic initiation; reauthorization requires confirmation patient remains on background inhaler therapy and documentation of clinical benefit or maintenance.
    RequirementDetails
    Step therapy required (Inbrija)
    Inbrija initial authorization requires trials and inadequate response or intolerance to medications from at least two different classes that reduce 'off' episodes (COMT inhibitors, dopamine agonists, MAO‑B inhibitors) unless contraindicated; annual reauthorization requires confirmation of symptomatic or clinical improvement or maintenance of benefit.
    RequirementDetails
    Step therapy required (example)
    For certain targeted therapies (example: PIQRAY), initial authorization requires prior endocrine‑based regimen(s) tried and failed; submission of that prior therapy documentation is required for approval.
    RequirementDetails
    Step therapy required (example)
    Some oncology agents require failure of specific prior agents before approval (example: Nubeqa requires prior trial and failure of both Erleada and Xtandi for initial authorization). Documentation of prior therapies must be provided.
    RequirementDetails
    Prior trial(s) required before approval
    For many psychiatric and neurologic agents, initial authorization requires documented prior trials and failures of specified alternatives (examples: aripiprazole plus another SGA before some antipsychotics; trial of ponatinib before SCEMBLIX for T315I mutation). Prior therapy details and outcomes must be submitted.
    RequirementDetails
    Prior trial(s) required as specified per product
    Many products list product‑specific prerequisite therapy requirements (examples: parathyroid hormone analogs require prior bisphosphonate trial; PI3K inhibitors require progression on endocrine regimens). Requests must include documentation of those prior trials or contraindications/intolerances.
    RequirementDetails
    Prior trial(s) required before approval (examples)
    Examples include: vasomotor symptom agents (e.g., VEOZAH) require failure/intolerance to at least two prior systemic hormone or non‑hormonal therapies from different classes; XIFAXAN for hepatic encephalopathy requires prior trial/failure of lactulose; some oncology agents require multiple prior systemic therapy lines. Documentation of these prior therapies is required for initial authorization.
    RequirementDetails
    See individual drug nodes for exact step requirements
    Step therapy and prior‑trial requirements vary by product; reviewers must consult the individual drug-specific criteria (e.g., XPOVIO, ZILBRYSQ, ZORYVE) for exact required prior agents, number of trials, and reauthorization expectations and submit the supporting documentation as specified in each drug's Other Criteria section.

    Site of Care and Medicare Part B vs Part D Considerations

    Note

    Describe administration and acquisition to determine Part B vs Part D

    For products with Part B vs Part D ambiguity (e.g., cortrophin, certain injectables), include a description of how the drug will be used/obtained and administration site to determine coverage under Part B or Part D.

    Billing Rule

    Home IVIG may be billed under Part B — include site‑of‑care details

    Home IV administration: IVIG formulations administered in the home for primary immune deficiency may be covered under Part B; include site‑of‑care details when submitting PA to clarify Part B vs Part D applicability.

    Billing Rule

    Provide site‑of‑care and acquisition details for coverage/billing determination

    Coverage and billing depend on site of care: infusion center, office, or pharmacy — provide how medication will be obtained and administered to support correct Part B vs Part D coverage determinations.

    Billing Rule

    Document administration/acquisition to determine Part B vs Part D

    Whether a drug is covered under Medicare Part B versus Part D may depend on administration and acquisition (self‑administered after training or filled at pharmacy and delivered to office may be Part D); document these details.

    Prior Authorization

    Initiate hyponatremia tolvaptan where sodium can be closely monitored; 30‑day limit

    Tolvaptan for hyponatremia must be initiated in a setting where serum sodium can be closely monitored (hospital outpatient) and is limited to a 30‑day course per the hyponatremia formulation criteria.

    Billing Rule

    State pharmacy vs provider‑office dispensing to determine Part D vs Part B

    Provide a clear statement of intended dispensing (pharmacy) or provider office administration to determine whether the product is covered under Part D or Part B; include who will acquire and administer the drug in PA documentation.

    Definitions and Diagnostic Thresholds

    inv-250: PA (prior authorization) definition
    Prior authorization (PA)Approval from the plan is required before dispensing the drug to avoid non‑coverage
    Formulary indicationDrugs requiring PA are listed with 'PA' on the formulary
    ConsequenceFailure to obtain PA may result in non-coverage of the drug
    inv-251: Cholestasis definition for authorization
    Cholestasis (authorization definition)Defined as one of: total serum bile acid > age‑adjusted ULN; increased conjugated bilirubin; GGT > age‑adjusted ULN; fat‑soluble vitamin deficiency; or intractable pruritus attributable to liver disease with drug‑induced pruritus ruled out
    Documentation requiredSubmit molecular genetic testing confirming diagnosis and lab evidence of cholestasis
    Prior therapiesInitial authorization requires failure/intolerance to ≥2 of cholestyramine, naltrexone, rifampin, ursodiol
    inv-252: Eosinophilic esophagitis diagnostic threshold
    Eosinophilic esophagitis diagnostic thresholdUpper endoscopy with biopsy showing ≥15 eosinophils per high‑power field (or 60 eos/mm2) plus compatible signs/symptoms
    Clinical signsExamples: dysphagia, food impaction, reflux, chest/abdominal pain, nausea/vomiting
    DocumentationSubmit endoscopy with biopsy result with authorization request
    inv-253: Eosinophilic esophagitis diagnostic threshold (duplicate extract)
    Eosinophilic esophagitis diagnostic threshold (duplicate)Upper endoscopy with biopsy showing ≥15 eos/HPF or 60 eos/mm2 required for diagnosis confirmation
    Required symptomsBiopsy must be accompanied by compatible clinical signs/symptoms
    Use in PACriterion used for biologic authorization for EoE indications
    inv-254: ITP platelet thresholds
    ITP platelet thresholds (definition)Platelet count <30 x 10^9/L OR <50 x 10^9/L with documented increased bleeding risk required for initial authorization
    Prior therapiesInitial ITP authorization requires failure/intolerance to ≥2 different ITP therapies or splenectomy
    ReauthorizationFirst reauthorization requires updated platelet count showing improvement
    inv-255: Part B prerequisite indicator
    Part B prerequisite indicatorIndicates whether Medicare Part B benefit prerequisite applies for the product (varies by product/site of care)
    ExamplesSome IV formulations administered in-home or in-office may be Part B; documentation of how drug will be obtained/used may be required
    ActionProvide site‑of‑care details when requested to determine Part B vs Part D
    inv-256: Child-Pugh score definition
    Child‑Pugh scoreBaseline hepatic function assessment (Child‑Pugh) required for some hepatically metabolized agents
    UseSubmit Child‑Pugh score or LFTs where product criteria request hepatic function
    ExclusionSevere hepatic impairment (Child‑Pugh C) may exclude therapy for specified drugs
    inv-257: GINA-recommended asthma regimen definition
    GINA‑recommended asthma regimenA regimen of at minimum maximally‑tolerated ICS + LABA + LAMA prior to biologic initiation
    Provider attestationPrescriber must attest regimen will continue after biologic initiation
    ReauthorizationReauthorizations often require confirmation patient remains on triple inhaler therapy
    inv-258: Severe renal impairment definition (CrCl <30 mL/min)
    Severe renal impairment definitionCreatinine clearance (CrCl) < 30 mL/min
    Usage impactCrCl <30 mL/min is exclusion for specified therapies; some entries specify eGFR <30 mL/min/1.73 m2
    DocumentationSubmit creatinine clearance or data to calculate it with authorization request
    inv-259: UFC >1.5x ULN (~>50 micrograms or 145 nmol)
    24‑hour urinary free cortisol (UFC) baseline requirement> 1.5 x ULN (approx >50 micrograms or 145 nmol)
    ContextRequired for initial authorization for Cushing's syndrome therapies (e.g., Recorlev/Signifor) and for reauthorization monitoring
    Additional testsECG (including QTcF) and LFTs also required per product criteria
    inv-260: High-intensity statin trial definition
    High‑intensity statin trial (Repatha)At least 8 weeks of high‑intensity statin therapy required before PCSK9 initiation for selected indications
    LDL goalPatient must have failed to achieve LDL <70 mg/dL despite statin trial for certain ASCVD/HoFH indications
    AlternativesStatin intolerance or rhabdomyolysis may substitute for statin trial in specific scenarios
    inv-261: Uox threshold for Rivfloza
    24‑hour urinary oxalate (Uox) threshold for Rivfloza>= 0.7 mmol (normalized to BSA if <18 years)
    Renal function requirementeGFR >= 30 mL/min/1.73 m2 required for Rivfloza initiation
    Mutation confirmationAGXT mutation confirmed by enzyme analysis or genetic testing required
    inv-262: Baseline UFC requirement for Signifor
    Baseline 24‑hour urine free cortisol (UFC) requirement for Signifor/Recorlev> 1.5 x ULN (≈50 micrograms or 145 nmol)
    Associated testsECG including QTcF and liver function tests within 3 months required
    PrescriberRestricted to endocrinology for Cushing's syndrome agents
    inv-263: Rapidly progressing ADPKD definition
    Rapidly progressing ADPKD definitionPositive kidney cyst imaging plus Mayo Imaging Classification 1C–1E OR historical eGFR decline ≥3 mL/min/1.73 m2/year over 4 years OR PROPKD score >6
    DocumentationSubmit imaging classification, eGFR history, or PROPKD score with authorization
    Prescriber restrictionRestricted to nephrology
    inv-264: High risk for fracture definition
    High risk for fracture definitionHistory of hip or vertebral fracture; or fracture of proximal humerus/pelvis/distal forearm with T‑score between -1.0 and -2.5; or T‑score ≤ -2.5; or T‑score between -1.0 and -2.5 with FRAX thresholds
    Prior therapyPrior bisphosphonate trial often required before parathyroid hormone analogs
    DocumentationSubmit fracture history, BMD/T‑score, and FRAX as applicable
    inv-265: HFrEF definition (LVEF <45% guidance)
    HFrEF definitionHeart failure with reduced ejection fraction; many criteria reference LVEF <45% for vericiguat/Verquvo authorization
    Required background therapySubmission of guideline‑directed medical therapy (ACEi/ARB/sacubitril‑valsartan, beta‑blocker, MRA) at maximally tolerated doses is required
    Recent eventsEvidence of HF hospitalization within 6 months or outpatient IV diuretic within 3 months often required
    inv-266: PIK3CA mutation definition (tumor genetic requirement)
    PIK3CA mutation requirementTumor genetic test confirming presence of PIK3CA mutation required for Vijoice and similar targeted therapies
    DocumentationSubmit tumor mutation test result with authorization request
    ExclusionCoadministration with strong CYP3A4 inducers excludes therapy per product criteria

    Policy Background

    Background: This policy compiles the prior authorization criteria for prescription products on Independent Health’s Medicare Advantage Part D formularies effective 2026‑01‑01. It defines required documentation, prescriber specialty limits, age restrictions, product‑specific exclusions, and coverage durations (commonly 1 year, with some initial authorizations shorter). The scope applies to providers and pharmacies submitting PA requests for affected Medicare members and lists the clinical thresholds and test results required to establish medical necessity.